Mirum Pharmaceuticals (STU:08D) Float Percentage Of Total Shares Outstanding: 76.24% (As of Jul. 13, 2026)


STU:08D Mirum Pharmaceuticals Inc STU:08D
51 GF Score
Price €109.30
GF Value €67.40
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Mirum Pharmaceuticals STU:08D -2.10% 51 Float Percentage Of Total Shares Outstanding is 76.24% as of Jul. 13, 2026. GuruFocus rates STU:08D with a GF Score™ of 51/100 and a GF Value™ of €67.40 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Mirum Pharmaceuticals's float shares is 46.49 Mil. Mirum Pharmaceuticals's total shares outstanding is 60.98 Mil. Mirum Pharmaceuticals's float percentage of total shares outstanding is 76.24%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Mirum Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Mirum Pharmaceuticals's Institutional Ownership is 63.03%.

STU:08D
51GF Score
Mirum Pharmaceuticals Inc STU:08D
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mirum Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Mirum Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=46.49/60.98
=76.24%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 76.24% mean?
Mirum Pharmaceuticals (STU:08D) has a Float Percentage Of Total Shares Outstanding of 76.24% as of Jul. 13, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Mirum Pharmaceuticals and its competitors.
Is Mirum Pharmaceuticals' Float Percentage Of Total Shares Outstanding too high?
Mirum Pharmaceuticals' current Float Percentage Of Total Shares Outstanding is 76.24%. Overall, Mirum Pharmaceuticals has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Float Percentage Of Total Shares Outstanding compare to RYTM and SYRE?
Mirum Pharmaceuticals' Float Percentage Of Total Shares Outstanding of 76.24% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current Float Percentage Of Total Shares Outstanding is 76.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mirum Pharmaceuticals (STU:08D) is currently considered Significantly Overvalued. The stock's GF Value™ is €67.40, compared to a current price of €109.30 — trading 62.2% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 76.24%. Mirum Pharmaceuticals' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Mirum Pharmaceuticals (STU:08D), the current Float Percentage Of Total Shares Outstanding is 76.24% as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (STU:08D) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of €109.30 is trading 62.2% above its estimated GF Value™ of €67.40. GuruFocus considers Mirum Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:08D:

  • Float Percentage Of Total Shares Outstanding: 76.24%
  • GF Value™: €67.40 vs. price of €109.30 (62.2% above fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the STU:08D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
51GF Score

Get the complete analysis for STU:08D

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€109.30
Price
€67.40
GF Value